About: ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Creator	Becker, Stephan Lambe, Teresa Wells, Daniel Temperton, Nigel Kupke, Alexandra Gilbert, Sarah Grehan, Keith Padron-Regalado, Eriko Warimwe, George Hill, Adrian Khalaf Alharbi, Naif Sloan, Megan Thompson, Craig
Source	Elsevier; Medline; PMC
abstract	Abstract The Middle East respiratory syndrome coronavirus (MERS-CoV) has infected more than 1900 humans, since 2012. The syndrome ranges from asymptomatic and mild cases to severe pneumonia and death. The virus is believed to be circulating in dromedary camels without notable symptoms since the 1980s. Therefore, dromedary camels are considered the only animal source of infection. Neither antiviral drugs nor vaccines are approved for veterinary or medical use despite active research on this area. Here, we developed four vaccine candidates against MERS-CoV based on ChAdOx1 and MVA viral vectors, two candidates per vector. All vaccines contained the full-length spike gene of MERS-CoV; ChAdOx1 MERS vaccines were produced with or without the leader sequence of the human tissue plasminogen activator gene (tPA) where MVA MERS vaccines were produced with tPA, but either the mH5 or F11 promoter driving expression of the spike gene. All vaccine candidates were evaluated in a mouse model in prime only or prime-boost regimens. ChAdOx1 MERS with tPA induced higher neutralising antibodies than ChAdOx1 MERS without tPA. A single dose of ChAdOx1 MERS with tPA elicited cellular immune responses as well as neutralising antibodies that were boosted to a significantly higher level by MVA MERS. The humoral immunogenicity of a single dose of ChAdOx1 MERS with tPA was equivalent to two doses of MVA MERS (also with tPA). MVA MERS with mH5 or F11 promoter induced similar antibody levels; however, F11 promoter enhanced the cellular immunogenicity of MVA MERS to significantly higher magnitudes. In conclusion, our study showed that MERS-CoV vaccine candidates could be optimized by utilising different viral vectors, various genetic designs of the vectors, or different regimens to increase immunogenicity. ChAdOx1 and MVA vectored vaccines have been safely evaluated in camels and humans and these MERS vaccine candidates should now be tested in camels and in clinical trials.
has issue date	2017-06-27(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2017.05.032
bibo:pmid	28579232
has license	els-covid
sha1sum (hex)	f3c5dbfd682af9f81d55a8feda2e808a0b4f22a0
schema:url	https://doi.org/10.1016/j.vaccine.2017.05.032
resource representing a document's title	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
has PubMed Central identifier	PMC5516308
has PubMed identifier	28579232
schema:publication	Vaccine
resource representing a document's body	covid:f3c5dbfd682af9f81d55a8feda2e808a0b4f22a0#body_text
is schema:about of	named entity 'infected' named entity 'infection' named entity 'induced' named entity 'spike' named entity 'doses' named entity 'leader sequence' named entity 'vectors' named entity 'MERS-CoV' covid:arg/f3c5dbfd682af9f81d55a8feda2e808a0b4f22a0 named entity 'prime-boost' named entity 'F11' named entity 'tPA' named entity 'camels' named entity 'optimized' named entity 'clinical trials' named entity 'tPA' named entity 'antiviral drugs' named entity 'antibodies' named entity 'believed' named entity 'MERS-CoV' named entity 'contained' named entity 'gene' named entity 'gene' named entity 'plasminogen activator' named entity 'F11' named entity 'vaccines' named entity 'cellular immune responses' named entity 'evaluated' named entity 'dose' named entity 'dose' named entity 'driving' named entity 'produced' named entity 'vaccines' named entity 'asymptomatic' named entity 'MERS-CoV' named entity 'tPA' named entity 'cellular immune responses' named entity 'vaccines' named entity 'Middle East respiratory syndrome coronavirus' named entity 'MERS-CoV' named entity 'gene' named entity 'vaccines' named entity 'prime-boost' named entity 'virus' named entity 'vector' named entity 'leader sequence' named entity 'vaccine' named entity 'MERS-CoV' named entity 'mice' named entity 'camel' named entity 'viruses' named entity 'antibodies' named entity 'immunogenicity' named entity 'transgenic mice' named entity 'conjugated' named entity 'potency' named entity 'statistically significantly' named entity 'Neutralisation' named entity 'mice' named entity 'blood samples' named entity 'incubation' named entity 'MERS' named entity 'human clinical trials' named entity 'MERS-CoV' named entity 'plasmids' named entity 'BALB/c' named entity 'risk factor' named entity 'seronegative' named entity 'antibody'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software